title: Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.
abstract: Sarcomas are heterogeneous and aggressive mesenchymal tumors. Histological grading has so far been the best predictor for metastasis-free survival, but it has several limitations, such as moderate reproducibility and poor prognostic value for some histological types. To improve patient grading, we performed genomic and expression profiling in a training set of 183 sarcomas and established a prognostic gene expression signature, complexity index in sarcomas (CINSARC), composed of 67 genes related to mitosis and chromosome management. In a multivariate analysis, CINSARC predicts metastasis outcome in the training set and in an independent 127 sarcomas validation set. It is superior to the Fédération Francaise des Centres de Lutte Contre le Cancer grading system in determining metastatic outcome for sarcoma patients. Furthermore, it also predicts outcome for gastrointestinal stromal tumors (GISTs), breast carcinomas and lymphomas. Application of the signature will permit more selective use of adjuvant therapies for people with sarcomas, leading to decreased iatrogenic morbidity and improved outcomes for such individuals.
authors.affiliation: Département de Pathologie, Institut Bergonié, Bordeaux, France. chibon@bergonie.org
authors.forename: Frédéric
authors.initials: F
authors.lastname: Chibon
authors.forename: Pauline
authors.initials: P
authors.lastname: Lagarde
authors.forename: Sébastien
authors.initials: S
authors.lastname: Salas
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Pérot
authors.forename: Véronique
authors.initials: V
authors.lastname: Brouste
authors.forename: Franck
authors.initials: F
authors.lastname: Tirode
authors.forename: Carlo
authors.initials: C
authors.lastname: Lucchesi
authors.forename: Aurélien
authors.initials: A
authors.lastname: de Reynies
authors.forename: Audrey
authors.initials: A
authors.lastname: Kauffmann
authors.forename: Binh
authors.initials: B
authors.lastname: Bui
authors.forename: Philippe
authors.initials: P
authors.lastname: Terrier
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bonvalot
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
authors.forename: Dominique
authors.initials: D
authors.lastname: Vince-Ranchère
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Françoise
authors.initials: F
authors.lastname: Collin
authors.forename: Louis
authors.initials: L
authors.lastname: Guillou
authors.forename: Agnès
authors.initials: A
authors.lastname: Leroux
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Coindre
authors.forename: Alain
authors.initials: A
authors.lastname: Aurias
mesh_terms: D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005544:Forecasting; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D012509:Sarcoma / Q000235:genetics* / Q000473:pathology*; D016896:Treatment Outcome